Raymond James reiterated a Strong Buy rating and $68 price target on Liquidia, with the analyst saying the firm is flagging Liquidia strength due to what it perceives to be as positive readthrough from the recent Supreme Court decision in Hikma v. Amarin. While this case is not an apples-to-apples comparison to the highly-anticipated '327 patent dispute decision, the firm does see this as generally positive readthrough for Liquidia, whose downside floor continues to rise. The firm also notes there could be a chance this means the '327 decision could be a more imminent event.
